Atara Biotherapeutics Inc

Compare

1,161 Followers

ATRA Stock Chart & Stats

$15.79

-$1.12(-6.68%)

At close: Jan 08 4:00 PM EST

$15.79

-$1.12(-6.68%)

Day’s Range― - ―

52-Week Range$5.01 - $18.71

Previous CloseN/A

Volume32.09K

Average Volume (3M)57.82K

Market Cap

$98.74M

Enterprise Value$131.17M

Total Cash (Recent Filing)$22.32M

Total Debt (Recent Filing)$15.43M

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Nov 18, 2025

EPS Estimate

-0.67

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.19

Shares Outstanding7,023,032

10 Day Avg. Volume44,861

30 Day Avg. Volume57,818

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-1.02

Price to Sales (P/S)0.77

P/FCF Ratio-1.45

Enterprise Value/Market Cap1.33

Enterprise Value/Revenue0.70

Enterprise Value/Gross Profit0.86

Enterprise Value/Ebitda9.17

Forecast

1Y Price Target

$16.00

Price Target Upside1.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial MilestoneIf the FDA approves tab-cel, it will trigger a $40 million milestone payment from Pierre Fabre to Atara, with additional commercial milestones and double-digit tiered royalties also possible.

Financial PerformanceAtara recorded a significant improvement in financial results for 2Q25, with net earnings per share far exceeding prior forecasts.

Regulatory ApprovalFDA has accepted the tab-cel resubmission for priority review, a meaningful step toward first approved therapy in US for EBV+ PTLD.

Bears Say

Manufacturing IssuesInitial BLA was rejected by FDA due to a third-party manufacturing issue, without request for additional clinical data.

Regulatory RisksRisks include the potential rejection of the tab-cel BLA resubmission by the FDA and setbacks with other pipeline candidates.

Atara Biotherapeutics News

Atara Biotherapeutics Announces Significant Workforce Reduction

An announcement from Atara Biotherapeutics ( ($ATRA) ) is now available. On October 6, 2025, Atara Biotherapeutics announced...

24d ago

ATRA

Atara Biotherapeutics Reduces Board Size, Appoints New Chair

Atara Biotherapeutics ( ($ATRA) ) has issued an update. On September 2, 2025, Atara Biotherapeutics announced a strategic...

2M ago

ATRA

Atara Biotherapeutics: Hold Rating Amid Tab-cel Developments and Financial Uncertainty

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on...

2M ago

ATRA

Atara Biotherapeutics reports Q2 EPS 19c vs. ($3.10) last year

Cash, cash equivalents and short-term investments as of June 30, 2025, totaled $22.3 million, as compared to $13.8...

3M ago

ATRA

ATRA Upcoming Earnings Report: What to Expect?

Atara Biotherapeutics Inc (ATRA) is scheduled to report 2nd quarter earnings on 08/11/2025. Regarding Q2 estimates, Wall Street...

3M ago

ATRA

Atara Biotherapeutics announces FDA acceptance of tabelecleucel BLA

Atara Biotherapeutics (ATRA) and Pierre Fabre Pharmaceuticals, or PFP, announced the acceptance by FDA of the Biologics License...

3M ago

ATRA

Atara Biotherapeutics announces FDA acceptance of BLA for tabelecleucel

Atara Biotherapeutics (ATRA) announced that the FDA has accepted the filing of its biologics license application for tabelecleucel...

3M ago

ATRA

Atara Biotherapeutics: Strategic Advancements and Financial Stability Support Buy Rating

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on Atara Biotherapeutics. The associated price target...

4M ago

ATRA

Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA

Atara Biotherapeutics ( ($ATRA) ) has shared an update. On July 14, 2025, Atara Biotherapeutics announced the resubmission...

4M ago

ATRA

Atara Biotherapeutics Holds Annual Stockholders Meeting

Atara Biotherapeutics ( ($ATRA) ) has provided an update. On June 10, 2025, Atara Biotherapeutics held its annual...

5M ago

ATRA

Atara Biotherapeutics appoints Huang, Subramanian to board of directors

Atara Biotherapeutics (ATRA) announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective...

6M ago

ATRA

Atara Biotherapeutics Reports Strong Q1 2025 Results

Atara Biotherapeutics Inc ( ($ATRA) ) has released its Q1 earnings. Here is a breakdown of the information...

6M ago

ATRA

Atara Biotherapeutics Announces $16M Stock Offering

Atara Biotherapeutics ( ($ATRA) ) has shared an announcement. On May 14, 2024, Atara Biotherapeutics entered into an...

6M ago

ATRA

Buy Rating for Atara Biotherapeutics: Strategic Focus and Financial Positioning Ahead of Key FDA Meeting

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report), retaining...

6M ago

ATRA

ATRA FAQ

What was Atara Biotherapeutics Inc’s price range in the past 12 months?

Atara Biotherapeutics Inc lowest stock price was $5.00 and its highest was $18.70 in the past 12 months.

What is Atara Biotherapeutics Inc’s market cap?

Atara Biotherapeutics Inc’s market cap is $98.74M.

When is Atara Biotherapeutics Inc’s upcoming earnings report date?

Atara Biotherapeutics Inc’s upcoming earnings report date is Nov 18, 2025 which is in 19 days.

How were Atara Biotherapeutics Inc’s earnings last quarter?

Atara Biotherapeutics Inc released its earnings results on Aug 11, 2025. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.256.

Is Atara Biotherapeutics Inc overvalued?

According to Wall Street analysts Atara Biotherapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atara Biotherapeutics Inc pay dividends?

Atara Biotherapeutics Inc does not currently pay dividends.

What is Atara Biotherapeutics Inc’s EPS estimate?

Atara Biotherapeutics Inc’s EPS estimate is -0.67.

How many shares outstanding does Atara Biotherapeutics Inc have?

Atara Biotherapeutics Inc has 7,023,032 shares outstanding.

What happened to Atara Biotherapeutics Inc’s price movement after its last earnings report?

Atara Biotherapeutics Inc reported an EPS of $0.19 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 11.822%.

Which hedge fund is a major shareholder of Atara Biotherapeutics Inc?

Among the largest hedge funds holding Atara Biotherapeutics Inc’s share is Woodline Partners LP. It holds Atara Biotherapeutics Inc’s shares valued at 0.

Atara Biotherapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-68.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atara Biotherapeutics Inc

Atara Biotherapeutics (ATRA) is a clinical-stage biotechnology company focused on developing innovative T-cell immunotherapy treatments for patients with cancer and autoimmune diseases. The company specializes in allogeneic T-cell therapies, leveraging its proprietary technology to create off-the-shelf products that aim to harness the immune system to fight diseases. Atara's core products include ATA188, a T-cell therapy targeting Epstein-Barr virus-associated diseases, and ATA3219, which is aimed at treating various malignancies.

Atara Biotherapeutics (ATRA) Earnings & Revenues

Historic Earnings Reports

ATRA Stock 12 Month Forecast

Average Price Target

$16.00

▲(1.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","12":"$12","19":"$19","8.5":"$8.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,8.5,12,15.5,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.34,12.621538461538462,12.903076923076924,13.184615384615384,13.466153846153846,13.747692307692308,14.02923076923077,14.310769230769232,14.592307692307692,14.873846153846154,15.155384615384616,15.436923076923076,15.71846153846154,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.34,12.621538461538462,12.903076923076924,13.184615384615384,13.466153846153846,13.747692307692308,14.02923076923077,14.310769230769232,14.592307692307692,14.873846153846154,15.155384615384616,15.436923076923076,15.71846153846154,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.34,12.621538461538462,12.903076923076924,13.184615384615384,13.466153846153846,13.747692307692308,14.02923076923077,14.310769230769232,14.592307692307692,14.873846153846154,15.155384615384616,15.436923076923076,15.71846153846154,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.12,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.11,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1719792000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.14,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >